Free Trial
TSE:PRN

Profound Medical Q3 2026 Earnings Results & Report

Profound Medical logo
C$11.32 +0.99 (+9.58%)
As of 02:46 PM Eastern

Profound Medical reported Q3 2026 earnings on November 5, 2026. The company reported EPS of -C$0.30, while revenue was C$13.99 million.

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
After Market Closes

Profound Medical EPS Results

Actual EPS
-C$0.30
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 7 quarters

Profound Medical Revenue Results

Actual Revenue
C$13.99 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Profound Medical Q3 2026 Earnings FAQ

Profound Medical (TSE:PRN) reported earnings of -C$0.30 per share for Q3 2026. The report was announced on Thursday, November 5, 2026.

Profound Medical reported revenue of C$13.99 million for Q3 2026.

Profound Medical Earnings Headlines

Profound Medical to Present at Stifel Healthcare Conference
Profound Medical (PRN) AI Stock Analysis
Your Social Security check is scheduled for a 22% cut
The U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.tc pixel
See More Profound Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Profound Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Profound Medical and other key companies, straight to your email.

About Profound Medical

Profound Medical (TSE:PRN), together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.

View Profound Medical Profile